Overview

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Status:
Completed

Trial end date:
2015-09-21

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetics as well as the safety and tolerability of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

Astellas Pharma Europe B.V.

Treatments:

Mirabegron